This international survey revealed major limitations in NAFLD/NASH management: delayed referrals, suboptimal screening, and absence of reliable tools for diagnose active steatohepatitis. Most respondents used multiple noninvasive fibrosis tests but had not used cT1, underscoring unmet need; LiverMultiScan cT1 could fill this diagnostic and monitoring gap.